HumanexaHumanexaHumanexa
WelcomeSignalsScenario AnalysisRegulatoryStrategyInsightsPricing

Workspace

Workspace

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAsafety guidance72% confidence

Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07

Source: MHRA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial.

Regulatory Analysis

Aspar Pharmaceuticals Ltd is recalling specific batches distributed in Aspar, Almus and Numark livery. The batches are being recalled as a precautionary measure following findings of foil perforations in some blisters.

Supporting Context

Therapeutic area
Oncology · Liver Cancer
Sub-indication
Liver Cancer

Related signal: Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial

Source

View source document

Related Signal

Open signal — Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
PrivacyTermsRefund PolicyDisclaimer

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.